Perfan

Perfan - General Information

Perfan is a selective phosphodiesterase inhibitor with vasodilating and positive inotropic activity that does not cause changes in myocardial oxygen consumption. It is used in patients with congestive heart failure. Trials were halted in the U.S., but the drug is used in various countries.

Pharmacology of Perfan

Perfan is a phosphodiesterase inhibitor (type III) that increases the force of contraction of the heart and dilates blood vessels. In June 2005, Myogen announced that they were discontinuing development of enoximone due to negative results. The drug is approved for use in the UK.

Additional information about Perfan

Perfan Indication: For the treatment of congestive heart failure.
Mechanism Of Action: Further research is required to determine accurately the mechanism of action of drugs with phosphodiesterase inhibitory activity.
Drug Interactions: Not Available
Food Interactions: Not Available
Generic Name: Enoximone
Synonyms: Not Available
Drug Category: Cardiotonic Agents; Phosphodiesterase Inhibitors; Vasodilator Agents
Drug Type: Small Molecule; Approved; Investigational

Other Brand Names containing Enoximone: Perfan;
Absorption: Bioavailabvility is 50% following oral administration.
Toxicity (Overdose): Not Available
Protein Binding: 85%
Biotransformation: Hepatic oxidation
Half Life: 4-10 hours
Dosage Forms of Perfan: Solution Oral
Chemical IUPAC Name: 4-methyl-5-(4-methylsulfanylbenzoyl)-1,3-dihydroimidazol-2-one
Chemical Formula: C12H12N2O2S
Enoximone on Wikipedia: https://en.wikipedia.org/wiki/Enoximone
Organisms Affected: Humans and other mammals